The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Immuno-Oncology Drugs Market Over The Period 2026–2030?
The immuno-oncology drugs market has experienced substantial expansion in recent years. Projections indicate a rise from $120.37 billion in 2025 to $136.15 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.1%. Historically, this growth stemmed from factors such as the restricted accessibility of immuno-oncology drugs, the dependence on traditional chemotherapy, the rising incidence of cancers like melanoma and lung cancer, expanding research efforts centered on oncology, and the swift regulatory clearances for monoclonal antibodies.
The immuno-oncology drugs market is projected for substantial expansion in the upcoming years. This market is anticipated to reach $226.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this growth during the forecast period include advancements in bispecific antibodies and oncolytic virus therapies, the spread of personalized immunotherapy solutions, greater investment in adoptive cell transfer therapies, increasing healthcare spending on cancer treatment, and the incorporation of digital platforms for patient oversight and clinical studies. Key trends anticipated for the forecast timeframe encompass the growing acceptance of immune checkpoint inhibitors for various cancer types, an increase in the creation of cancer vaccines and adoptive cell therapies, a heightened emphasis on individualized immuno-oncology treatments, the broadening of immunotherapy programs offered by hospitals and ambulatory surgical centers, and an uptick in clinical trials and research related to monoclonal antibodies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp
Which Major Factors Are Driving The Expansion Of The Immuno-Oncology Drugs Market?
The rising incidence of cancer cases is anticipated to spur the expansion of the immuno-oncology drugs market in the future. Cancer involves the uncontrolled multiplication of abnormal cells, which can potentially spread throughout the body and impair regular bodily functions. This increase in cancer diagnoses is driven by elements such as aging populations, evolving lifestyles, and advancements in cancer detection methods. Immuno-oncology drugs facilitate this by activating the body’s immune system to target and eradicate cancer cells, thus offering more effective and precise treatment avenues. For instance, in 2023, Cancer Australia, an Australia-based government agency, estimated 164,694 new cancer cases were diagnosed and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most common, while rare cancers accounted for about one-third of diagnoses and 42% of deaths. Therefore, the increasing frequency of cancer cases is stimulating the growth of the immuno-oncology drugs market.
How Is The Immuno-Oncology Drugs Market Divided Into Its Major Segments?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
How Are Trends Transforming The Immuno-Oncology Drugs Market Landscape?
Leading firms within the immuno-oncology drugs market are engaging in partnerships to create and market an innovative checkpoint antibody, aiming to improve the efficacy of cancer therapies. Such strategic alliances promote innovation by facilitating the exchange of knowledge across various disciplines, accelerating the progress of combination therapies, tailored treatments, and new drug delivery methods. A notable example occurred in March 2023 when BioNTech SE, a company headquartered in Germany, formed a partnership with OncoC4 Inc, a US-based pharmaceutical entity. Their agreement is for the joint development and commercialization of a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate designated as ONC-392. The objective of this collaboration is to broaden cancer treatment alternatives across various solid tumor indications.
Who Are The Prominent Organizations Shaping The Immuno-Oncology Drugs Market?
Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.
Read the full immuno-oncology drugs market report here:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report
Which Region Currently Holds The Largest Share Of The Immuno-Oncology Drugs Market?
North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Immuno-Oncology Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3455&type=smp
Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company
Veterinary Laboratory Testing Services Market Report 2026
Dermatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model